As of 2025-05-31, the Fair Value of NeuBase Therapeutics Inc (NBSE) is -18.31 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.38 USD, the upside of NeuBase Therapeutics Inc is -4,943.03%.
With the market price of 0.38 USD and our fair value calculation, NeuBase Therapeutics Inc (NBSE) is not a good investment. Investing in NBSE stocks now will result in a potential loss of 4,943.03%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2022-12-31 | 5Y Avg | |
| Net income | -26.13 | -17.38 | -25.41 | -33.78 | -4.37 | -21.41 |
| YoY growth | -97.36% | 33.49% | -46.20% | -32.94% | 87.06% | -11.19% |
| Market Cap (mil) | 1.42 |
| P/E | |
| Forward P/E | -0.10x |
| EPS | -3.66 |
| Avg earnings growth rate | -11.19% |
| TTM earnings | -13.73 |